KYNB
Kyntra Bio Inc. Common Stock (KYNB)
Healthcare • NASDAQ • $6.95-2.11%
- Symbol
- KYNB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.95
- Daily Change
- -2.11%
- Market Cap
- $28.13M
- Trailing P/E
- N/A
- Forward P/E
- -0.68
- 52W High
- $12.60
- 52W Low
- $4.85
- Analyst Target
- $43.00
- Dividend Yield
- N/A
- Beta
- 1.04
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerl…
Company websiteResearch KYNB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.